People who receive a pancreas transplant typically live far longer than those who remain on the waiting list, with median survival ranging from roughly 14 to 18 years depending on the type of transplant and how healthy the recipient’s kidneys are. A large analysis covering 21 years of registry data found that the most common procedure, a simultaneous pancreas-kidney transplant, carried a median survival of 17 years, compared with just 2.7 years for patients who stayed on the waitlist. Those numbers are averages, of course, and individual outcomes depend heavily on age, cardiovascular health, how well the donor organ matches, and whether the recipient stays on top of lifelong immunosuppressive medications.
Survival Numbers by Transplant Type
Pancreas transplants fall into three categories, and the survival picture differs across them. A simultaneous pancreas-kidney transplant (SPK) is performed when a person with type 1 diabetes also has kidney failure. It is the most common type and tends to produce the best long-term survival. Registry data show a median survival of about 17 years for SPK recipients, with an average of 11.7 life-years gained compared to staying on the waitlist.1Journal of Health Care and Research. Survival Advantages of Pancreas Transplantation A pancreas transplant alone (PTA), performed in diabetic patients whose kidneys still work, had the longest median survival at 18.3 years, though these patients also tended to be healthier at the time of transplant. The pancreas-after-kidney transplant (PAK), done in people who previously received a kidney, showed a median survival of about 14.3 years.
Those numbers may seem counterintuitive at first. PTA recipients already have working kidneys, so they start from a healthier baseline. SPK recipients, despite needing two organs, benefit from the combined surgery addressing both their diabetes and kidney failure at once. PAK recipients face a middle ground: they have already endured one transplant and are already on immunosuppression, but the additional pancreas procedure brings its own surgical risks. A five-year follow-up comparing SPK and PAK found that patient survival and pancreas graft survival were essentially equivalent between the two approaches at the five-year mark, with patient survival above 95% in both groups.2PubMed. Pancreas survival in simultaneous pancreas-kidney and pancreas-after-kidney transplantations: a five-year follow-up report
How Age Shapes the Outlook
Age matters, though perhaps not as severely as you might expect. A dual-center study comparing younger and older recipients found that ten-year patient survival was about 82% in the younger group and about 66% in the older group.3PubMed Central. Recipient age and outcome after pancreas transplantation: a retrospective dual‐center analysis That gap is real but doesn’t mean older patients should be turned away. The same study found that when you looked at pancreas graft survival excluding deaths from unrelated causes, the difference between age groups mostly disappeared. In other words, the graft itself held up about equally well regardless of age. The extra deaths in the older group came from other health problems, particularly cardiovascular disease.
A separate analysis reinforced this, concluding that patients aged 45 to 54, as well as those 55 and older, had acceptable long-term patient and graft survival despite experiencing more cardiovascular events than younger recipients.4PubMed. Pancreas transplantation in older patients is safe, but patient selection is paramount The takeaway from the transplant community has been that chronological age alone should not disqualify someone. What matters more is the overall burden of diabetes-related damage, especially to the heart and blood vessels, at the time of surgery.
What Actually Threatens Long-Term Survival
Understanding what goes wrong after a pancreas transplant helps explain why some people live two decades while others don’t make it past a few years. The risks change over time. In the early months, surgical complications and infections dominate. In the long run, cardiovascular disease becomes the primary killer.
An older but frequently cited study of mortality after pancreas transplants found that infection was the most common cause of early death, and six of eight infection-related deaths were linked to surgical complications.5PubMed. Mortality after vascularized pancreas transplantation A more recent cohort with a median follow-up of eight years found that cardiovascular and cerebrovascular disease caused about 25% of deaths, while infection and sepsis accounted for 20%.6Transplantation. Systematic Study of Causes of Death and Allograft Loss After Pancreas Transplantation in the Modern Era Even among patients whose transplanted pancreas was still working perfectly at the time of death, a meaningful fraction died from diabetes-related causes that had taken root years before the transplant. In the SPK group, about 29% of deaths occurring after the first 90 days were attributed to cardiovascular disease, diabetic complications, or sudden death, all in patients with functioning grafts.7American Journal of Transplantation. Mortality Assessment for Pancreas Transplants
This underscores an important point: a pancreas transplant eliminates the need for insulin and normalizes blood sugar, but it cannot reverse all the damage that years of diabetes have already done. If coronary artery disease or other vascular damage is already advanced at the time of surgery, the transplant may not be enough to prevent a cardiovascular event down the road.
Graft Loss and Why It Happens
Surviving as a patient and keeping the transplanted pancreas alive are related but distinct questions. You can lose the graft and still be alive, returning to insulin injections while your own health continues. Among the main causes of graft failure, chronic rejection is the leading long-term threat, affecting roughly 10% of recipients.8PubMed Central. Late complications of pancreas transplant Blood clots in the transplanted organ, known as graft thrombosis, tend to happen almost immediately after surgery and are a major cause of early graft loss. A study of 391 cases found that among grafts that failed, the single largest category was actually death with a functioning graft (about 44% of losses), followed by thrombosis (about 29%) and chronic rejection (about 9%). Thrombosis struck within days, while chronic rejection took an average of about two and a half years to cause graft failure.9Scientific Reports. Different timing and risk factors of cause-specific pancreas graft loss after simultaneous pancreas kidney transplantation
Cytomegalovirus (CMV) infection is another threat to the graft. In a study of 471 pancreas transplant recipients, about a quarter developed clinically significant CMV infection, typically appearing around seven or eight months after transplant. Among those who got CMV, the risk of graft failure roughly doubled compared to recipients who avoided the virus.10PubMed Central. Risk of Cytomegalovirus Infection and Subsequent Allograft Failure after Pancreas Transplantation Transplant centers now routinely screen for CMV status in both donors and recipients and prescribe antiviral prophylaxis, but the infection remains a persistent concern.
Cardiovascular Benefits of a Working Pancreas Graft
One of the strongest arguments for pancreas transplantation is its effect on the cardiovascular system. People with long-standing type 1 diabetes accumulate damage to their blood vessels from years of fluctuating blood sugar, and this vascular damage is what ultimately kills many of them. A successful transplant normalizes blood sugar almost immediately, and the downstream cardiovascular effects are measurable within a couple of years.
A study tracking carotid artery thickness (a marker of atherosclerosis) found that it improved within two years of a successful pancreas transplant, independent of changes in cholesterol, blood pressure, or weight.11PubMed. Pancreas transplantation improves vascular disease in patients with type 1 diabetes Another study of pancreas-alone transplants found that cholesterol levels dropped, blood pressure improved, and several measures of heart structure and function got better after the procedure.12PubMed. Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients These improvements are not trivial: cardiovascular disease is the number-one killer of diabetic patients both on the waitlist and after transplant, so anything that slows its progression directly affects how long you live.
Nerve and Eye Benefits
Beyond the heart, a working pancreas graft can stabilize or even reverse some of the nerve and eye damage that diabetes causes. A systematic review looking across 16 studies on neuropathy found that about 88% showed measurable improvements in nerve function after transplantation.13PubMed. The impact of pancreas transplantation on diabetic complications: A systematic review This aligns with earlier work published in the New England Journal of Medicine showing that neuropathy tended to improve after transplantation, with significant gains in motor and sensory nerve function appearing by 12 months and continuing at the 42-month mark.14PubMed. Effects of pancreatic transplantation on diabetic neuropathy
For diabetic retinopathy, the picture is more mixed. The same systematic review found that about half of the studies showed improvement in retinopathy, while the other half showed stabilization but not reversal.13PubMed. The impact of pancreas transplantation on diabetic complications: A systematic review Stabilization is still meaningful, since untreated diabetic retinopathy tends to worsen progressively. The difference between nerves and eyes likely has to do with how well each tissue can repair itself once blood sugar is normalized. Nerve fibers regenerate slowly but measurably; damage to the tiny blood vessels in the retina is harder to undo.
Donor Selection and Organ Matching
The quality of the donor organ plays a significant role in how long the transplant lasts. Several donor-related risk factors have been identified, including advanced donor age (generally over 50), high body mass index (over 30), cause of death such as stroke, prolonged time the organ spends in cold storage, and the macroscopic condition of the pancreas itself at the time of retrieval.15PubMed Central. Donor risk factors in pancreas transplantation Older donor age and longer preservation times have been linked to worse graft survival, and the volume of transplants a center performs also influences outcomes.16Transplantation Reports. Pancreas transplantation from donors after cardiac death – The US experience
Immunological matching between donor and recipient also affects how long the graft survives. Better matching at certain immune markers (HLA-DR) and blood-group compatibility have been shown to improve pancreas graft survival.17PubMed. Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution In practice, the urgency of the patient’s condition sometimes means accepting a less-than-perfect match. But centers that can allocate organs with closer immunological compatibility tend to see better results.
The Burden of Lifelong Immunosuppression
Every pancreas transplant recipient must take immunosuppressive drugs for as long as the graft is functioning, and these medications carry their own health costs. The standard combination has evolved over the decades, but drug-related side effects and toxicities remain a real drag on long-term outcomes.18PubMed. Trends in immunosuppression after pancreas transplantation: what is in the pipeline? Calcineurin inhibitors, which form the backbone of most regimens, can cause kidney damage over time, a bitter irony for patients who may have just received a new kidney alongside their pancreas. Newer strategies aim to reduce or avoid calcineurin inhibitor exposure, and research into antibody-mediated rejection has introduced additional treatment options, but no drug-free maintenance protocol has emerged as reliable.
Sticking with the medication schedule is critical. Research in kidney transplant recipients, who take similar immunosuppressive regimens, found that more than 40% showed some degree of nonadherence. The nonadherent group had significantly higher rates of graft loss and rejection compared to those who stayed compliant.19PubMed Central. Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes The same patterns apply to pancreas recipients. Taking twice-daily medications for years on end, dealing with side effects, and managing the cost of the drugs all create opportunities for doses to be missed. This is one of the most modifiable risk factors for graft longevity, yet it remains one of the most common problems.
What Happens When the Graft Fails
Losing a pancreas graft is not the end of the road. Retransplantation is an option, though it comes with higher surgical risks than a first transplant. A study of 52 pancreas retransplants found one-year patient survival of 96% and five-year patient survival of 89%, which are reassuring numbers. The graft itself fared less well, with one-year graft survival at 79% and five-year graft survival at 69%.20PubMed Central. Outcomes of pancreas retransplantation in patients with pancreas graft failure Acute rejection episodes and early surgical complications were the strongest predictors of graft loss after retransplantation. Simultaneous kidney-pancreas retransplantation tended to perform better than pancreas retransplantation alone, mirroring the pattern seen in first transplants.
For patients who are not candidates for retransplantation, or who prefer not to undergo another major surgery, the fallback is returning to exogenous insulin therapy. This isn’t a death sentence, but it does mean losing the metabolic stability and the protection against progressive diabetic complications that a functioning graft provides.
Factors That a Multivariable Analysis Actually Flags
When researchers run the numbers across large registries, several factors consistently surface as predictors of post-transplant mortality. A study published in JAMA identified recipient age, donor cause of death, the type of surgical drainage used, early complications like pancreatitis or leaks from the surgical connection, and rejection before the patient left the hospital as the factors most clearly tied to dying after a pancreas-alone transplant.21JAMA. Survival After Pancreas Transplantation in Patients With Diabetes and Preserved Kidney Function Some of those, like donor cause of death, are outside the recipient’s control. Others, like getting through the early postoperative period without a serious complication, depend heavily on the surgical team’s experience and the patient’s preoperative fitness.
This is where center volume enters the conversation. Higher-volume transplant centers consistently report better outcomes, likely because their surgical teams handle complications more routinely and their support staff are more attuned to the subtle signs of early rejection or infection. If you are evaluating whether to pursue a pancreas transplant, asking about a center’s annual volume and outcomes data is one of the more practical steps you can take.
How Pancreas Transplants Compare to Islet Cell Transplants
Islet cell transplantation is sometimes mentioned as a less invasive alternative. In this procedure, insulin-producing cell clusters are extracted from a donor pancreas and infused into the recipient’s liver through a catheter, avoiding major abdominal surgery. The appeal is obvious: no surgical wound to heal, shorter hospital stays, and lower early complication rates. However, pancreas transplantation remains the most effective method for establishing durable insulin independence in people with diabetes.22PubMed Central. Current status of pancreas and islet cell transplantation Islet transplants tend to lose function over time, with many recipients eventually needing to resume insulin injections within a few years. The full organ transplant, while a bigger operation, provides a more robust and longer-lasting supply of insulin-producing tissue. For younger patients who can tolerate major surgery, the whole-organ transplant generally offers a better shot at long-term insulin independence.
Islet cell transplantation still has a role, particularly for older patients or those whose surgical risk is too high for a full transplant. It can dramatically reduce hypoglycemic episodes and improve quality of life even when it doesn’t achieve complete insulin independence. The field is evolving, and newer encapsulation technologies aim to protect transplanted islets from immune attack without requiring as much immunosuppression. But for now, if the question is how long you can expect to be free of insulin and protected against progressive diabetic complications, the whole-organ transplant remains the stronger bet.